SYRS: Gunggung utang perusahaan Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals (SYRS) laboratories consistently develop oncology drugs, utilizing partner capacities without technical failures. The business relies on environmental standards, implementing energy saving and emission filtration within gene therapy centers. This daily price chart reflects a level of 0.00, confirming a critical funding shortage following clinical failures, despite the transparency of the restructuring and the scientific expertise of top management.

Total debt measures the company's aggregate liabilities, determining the interest burden and the risk of margin erosion during a period of expensive borrowing. By analyzing the debt history, an investor assesses the financial stability of Syros Pharmaceuticals (SYRS), which is currently critical for restructuring its R&D strategy following a decline in patent protection effectiveness and failed clinical trials.